Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis

Group 1 - Centessa Pharmaceuticals (NASDAQ:CNTA) is considered a promising stock under $50, with Truist raising its price target to $33 from $30 while maintaining a Buy rating [1] - Needham increased its price target for Centessa to $38 from $35, also with a Buy rating, anticipating continued momentum into 2026 driven by Phase 2a data for ORX-750 [2] - Oppenheimer resumed coverage with an Outperform rating and raised its price target to $62 from $40, highlighting Centessa's best-in-class orexin agonists and projected commercial launch in H1 2028 [3] Group 2 - Centessa is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering medicines [4]